Evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
EVENITY — AMGEN INC, approved 2019-12-20 (BLA761062).
6,311 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.